What is a stock summary page? Click here for an overview.
Business Description
Roquefort Therapeutics PLC
ISIN : GB00BMDQ2T15
Description
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.98 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | -0.36 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 0.6 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.58 | |||||
| 9-Day RSI | 35.22 | |||||
| 14-Day RSI | 38.16 | |||||
| 3-1 Month Momentum % | -59.21 | |||||
| 6-1 Month Momentum % | -60.26 | |||||
| 12-1 Month Momentum % | -61.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.79 | |||||
| Quick Ratio | 0.79 | |||||
| Cash Ratio | 0.69 | |||||
| Days Payable | 4227.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -967 | |||||
| Net Margin % | -872.5 | |||||
| FCF Margin % | -685 | |||||
| ROE % | -27.36 | |||||
| ROA % | -23.97 | |||||
| ROIC % | -26.57 | |||||
| ROC (Joel Greenblatt) % | -3368 | |||||
| ROCE % | -28.47 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 8 | |||||
| PB Ratio | 0.42 | |||||
| EV-to-EBIT | -1.48 | |||||
| EV-to-EBITDA | -1.49 | |||||
| EV-to-Revenue | 12.47 | |||||
| EV-to-FCF | -1.82 | |||||
| Earnings Yield (Greenblatt) % | -67.57 | |||||
| FCF Yield % | -55.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Roquefort Therapeutics PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 0.2 | ||
| EPS (TTM) (£) | -0.012 | ||
| Beta | -0.73 | ||
| 3-Year Sharpe Ratio | -0.68 | ||
| 3-Year Sortino Ratio | -0.88 | ||
| Volatility % | 91.1 | ||
| 14-Day RSI | 38.16 | ||
| 14-Day ATR (£) | 0.002888 | ||
| 20-Day SMA (£) | 0.018165 | ||
| 12-1 Month Momentum % | -61.25 | ||
| 52-Week Range (£) | 0.014 - 0.06775 | ||
| Shares Outstanding (Mil) | 154.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Roquefort Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Roquefort Therapeutics PLC Stock Events
| Event | Date | Price (£) | ||
|---|---|---|---|---|
| No Event Data | ||||
Roquefort Therapeutics PLC Frequently Asked Questions
What is Roquefort Therapeutics PLC(LSE:ROQ)'s stock price today?
The current price of LSE:ROQ is £0.02. The 52 week high of LSE:ROQ is £0.07 and 52 week low is £0.01.
When is next earnings date of Roquefort Therapeutics PLC(LSE:ROQ)?
The next earnings date of Roquefort Therapeutics PLC(LSE:ROQ) is 2025-04-25 Est..
Does Roquefort Therapeutics PLC(LSE:ROQ) pay dividends? If so, how much?
Roquefort Therapeutics PLC(LSE:ROQ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers